Ann: Trading Halt, page-43

No question they would. The PXS pipeline is really valuable. I have always worked under the assumption that Bronchitol will eventually be taken up by 10% of the PXS community as it is effective, safe and cheap. That would give PXS worldwide revenue of $200 million per annum in about 5 years or so. There is also a potential market for Bronchitol for Bronchiectasis in a subpopulation of patients with severe or moderate condition (not mild sufferers, that is why we got poor significance)

I think I understand why we are seeing a slower uptake of Bronchitol in Australia. Doctors do not want to harm patients that are stable on the current best standard of care (BSC) so they are very cautious in introducing new patients. I think that the reputation of B is growing and where patients are supported they will take up B in higher numbers.

Good luck for Tuesday all.